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Abstract   37 
Background & Aims: 38 
Despite the wide spectrum of experimental compounds tested in clinical trials, there is still no 39 
proven pharmacological treatment available for Fragile-X syndrome (FXS), since several 40 
targeted clinical trials with high expectations of success have failed to demonstrate significant 41 
improvements. Here we tested epigallocatechin-3-gallate (EGCG) as a treatment option for 42 
ameliorating core cognitive and behavioral features in FXS.  43 
Methods 44 
We conducted preclinical studies in Fmr1 knockout mice (Fmr1–/y) using novel object-45 
recognition memory paradigm upon acute EGCG (10 mg/kg) administration. Furthermore we 46 
conducted a double-blind placebo-controlled phase I clinical trial (TESFXS; NCT01855971). 47 
Twenty-seven subjects with FXS (18-55 years) were administered of EGCG (5-7 mg/kg/day) 48 
combined with cognitive training (CT) during 3 months with 3 months of follow-up after 49 
treatment discontinuation. 50 
Results 51 
Preclinical studies showed an improvement in memory in the novel object recognition 52 
paradigm. We found that FXS patients receiving EGCG+CT significantly improved cognition 53 
(visual episodic memory) and functional competence (ABAS II-Home Living skills) in everyday 54 
life compared to subjects receiving Placebo+CT. 55 
Conclusions 56 
Phase 2 clinical trials in larger groups of subjects are necessary to establish the therapeutic 57 
































Introduction  62 
Fragile-X syndrome (FXS) (OMIM, 300624) is the most common (1/4000 live births) cause of 63 
intellectual disability and autism of genetic origin. It is a trinucleotide repeat disorder caused 64 
by a CGG repeat expansion at the 5′-end of the FMR1 gene, which hypermethylation results in 65 
transcriptional silencing and loss of expression of Fragile-X mental retardation protein 66 
(FMRP). Brain alterations observed in FXS patients are linked to low concentrations of FMRP 67 
[1], a RNA binding protein that plays a pivotal role in synaptic function. Despite the wide 68 
spectrum of experimental compounds tested in clinical trials (i.e. selective antagonist of 5-69 
HT2B serotonin receptor, metabotropic glutamate receptor 5 (mGluR5) antagonist, or GABAB 70 
receptor agonists) [2], there is no pharmacological treatment available for ameliorating 71 
cognitive and behavioral features in FXS.  72 
We previously showed that epigallocatechin-3-gallate (EGCG), the major catechin in green tea 73 
leaves, elicited beneficial effects in intellectual disability. Specifically, in Down syndrome 74 
mouse models and patients, EGCG administered alone [3] or in combination with cognitive 75 
training, improved cognition and brain functional connectivity [4]. In fact, flavonoid-rich foods 76 
can beneficially influence normal cognitive function [5,6] and slow down cognitive decline in 77 
non-pathological aging. Mounting evidence suggests that Down syndrome and FXS share 78 
common alterations in signaling pathways relevant for neural plasticity and  learning and 79 
memory processes, such as PI3K, mTOR and ERK1/2 [7,8], that are targeted by EGCG 80 
[9,10]. We thus reasoned that EGCG could also rescue the cognitive alteration in FXS. 81 
We first performed a preclinical study in Fmr1 knockout mice (Fmr1−/y) to explore the possible 82 
effects of EGCG on cognitive function in an FXS model, and determine the more adequate 83 
dosage. Upon positive preclinical results, we performed a Phase 1 randomized, double-blind, 84 
placebo-controlled 6 months clinical trial to assess the safety and preliminarily clinical efficacy 85 















exploratory trial, we compared the effectiveness of EGCG plus cognitive training (CT) with 87 
placebo plus CT in an adult population with FXS. 88 
 89 
Materials and Methods 90 
1. Preclinical pharmacological studies 91 
Animals 92 
Fmr1 knockout mice (FVB.129P2-Pde6b+ Tyrc−chFmr1tm1Cgr/J) and WT mice (FVB.129P2-93 
Pde6b+ Tyrc−ch/AntJ) on a FVB background were purchased from The Jackson Laboratory 94 
and crossed to obtain Fmr1−/y and WT littermates. All experimental mice were bred in the 95 
Barcelona Biomedical Research Park (PRBB) Animal Facility. Mice were housed four per 96 
cage in a temperature (21°C ± 1°C) and humidity (55% ± 10%) controlled environment. Food 97 
and water were available ad libitum. Behavioral experiments were performed on 12-16 week 98 
old mice during the light phase of a 12h light-dark cycle (lights on at 8 a.m.), after mice were 99 
handled for 1 week. All animal procedures were approved by the local ethical committee 100 
(Comitè Ètic d’Experimentació Animal-Parc de Recerca Biomèdica de Barcelona, CEEA-101 
PRBB) and followed standard ethical guidelines (European Communities Directive 86/60-102 
EEC).  103 
Drugs and treatments 104 
Green tea extract (GTE) nutritional supplement containing 45% of EGCG (Life Extension 105 
Decaffeinated Mega Green Tea Extract; http://www.lifeextension.com/vitamins-106 
supplements/item00954/mega-green-tea-extract-decaffeinated), was dissolved in water and 107 
administered per oral route in a volume of 10 mL per kg body weight (50, 25 or 10 mg/kg of 108 
GTE, equivalent to 22.5, 11.25 and 4.5 mg/kg of EGCG, respectively).  109 















The novel object-recognition memory was assayed as described previously [11]. Briefly, on 111 
day one, mice were habituated for 10 minutes to an empty V-shaped maze (V-maze). The 112 
next day mice were reintroduced in the V-maze for 10 minutes where two identical objects had 113 
been positioned, one at the end of each arm. After the training period mice were randomly 114 
assigned to one of the dosages of EGCG (4.5, 11.25, or 22.5 mg/kg) or water groups, and 115 
placed back to their home-cage. Novel object-recognition memory was assessed 24h after 116 
training. Mice were reintroduced for 10 minutes in the V-maze where the object explored the 117 
day before (familiar) and a novel object was located at the end of the arms. The exploration 118 
time for both objects (familiar, F, and novel, N) was computed (tF y tN) by experienced 119 
observers blind to the experimental groups, and used to define a discrimination index (DI) 120 
following the formula: DI=(tN-tF)/tN+tF). DI values >0.3 indicate mouse discrimination between 121 
F and N objects, while DI<0.15 indicate lack of discrimination between objects [12]. 122 
Statistical analysis 123 
Results are reported as the mean ± S.E.M. Statistical comparisons (Student’s t-test between 124 
two groups or one-way analysis of variance (ANOVA) for multiple group comparisons) using 125 
the Statistica Software. Comparisons were considered statistically significant when P < 0.05. 126 
2. Clinical trial 127 
We performed a randomized, placebo-controlled, phase I, 6-month clinical trial (TESXF study; 128 
NCT01855971) at the Hospital del Mar Medical Research Institute (IMIM) of Barcelona aimed 129 
at investigating if cognitive training (CT) combined with a green tea extract nutritional 130 
supplement containing 45% of EGCG (5-7 mg/kg/day) could improve cognitive performance 131 
and adaptive functionality compared to CT combined with placebo in adults with FXS. The trial 132 
was approved by the local ethical committee (CEIC Parc de Salut Mar, ref. 2012/4781/I), and 133 
conducted according to the Declaration of Helsinki and Spanish guidelines and regulations 134 















Eligible participants were recruited from the Catalan Association of Fragile-X Syndrome, and 136 
two health centers specialized in intellectual disabilities (Parc Hospitalari Martí i Julià, Salt, 137 
and Villablanca Serveis Assistencials, Institut d´Investigació Sanitaria Pere Virgili, Reus). All 138 
enrolled participants clinically diagnosed as FXS patients had a reliable parent or caregiver 139 
ensuring administration of the medication and CT, and completing all visits. We initially 140 
planned to include adults of both genders with FXS, aged 18 to 45 years, but due to 141 
recruitment difficulties we finally extended the inclusion criteria to 55 years with any of the 142 
FMR1 genetic variations (full mutation, premutation or mosaic). As the molecular diagnosis for 143 
FXS was not available in several subjects, we had to confirm clinical diagnosis. Subjects with 144 
neurological disease other than FXS, relevant medical disease, unstable co-morbid mental 145 
disorder or under any treatment that could interfere with cognitive function were excluded from 146 
the study. Other exclusion criteria were: (i) having suffered from any major illness or 147 
undergoing major surgery in the last 3 months before the study; (ii) new medication in the 148 
month preceding the study; (iii) ingestion of vitamin or catechin supplements or non-steroidal 149 
anti-inflammatory drugs (NSAIDs) in the 2 weeks preceding the study; (iv) gastrointestinal, 150 
hepatic, renal or any other problems that may alter absorption, distribution, metabolism, or 151 
excretion of the drug. 152 
Participants, parents and/or legal guardians were informed of the protocol and gave their 153 
written informed consent. Rules for early termination of the study were predefined and 154 
included the observation of serious adverse events. The trial was analyzed by the intention-to-155 
treat (ITT) approach to provide unbiased comparisons among the treatment groups. 156 
Concerning missing data, an inverse probability weighting method was used, so that complete 157 
observations were weighted by the inverse of the estimated probabilities of being observed. 158 
Study enrollment, randomization, and retention were held from June 2013 to July 2015. 159 
Initially thirty-one patients were randomized but molecular diagnoses of four of them did not 160 















group). Therefore, twenty-seven patients (61% of those initially contacted, n=44) were 162 
randomly assigned to EGCG+CT or Placebo+CT group, using a random-number table and 163 
were included in the intention to treat analysis (12 in Placebo+CT and 15 in EGCG+CT 164 
group). One participant from the EGCG+CT and one from the Placebo+CT group dropped out 165 
from the trial. Both were evaluated at 3 months after randomization, and the subject receiving 166 
EGCG+CT was also evaluated at 6 months as the trial (both cases were included in statistical 167 
analyses, in one case the whole evaluation at 6 months is missing while in the other case the 168 
biochemical and the neurophysiological variables are unavailable; see CONSORT diagram, 169 
Fig. 2). Neuropsychological data from these participants were included in the analyses. The 170 
demographics were similar in the groups receiving EGCG+CT and Placebo+CT (Table 1). 171 
Regarding intellectual disability level (intellectual quotient, IQ), the distribution of individuals 172 
with severe (IQ ≤ 40) and moderate to mild (IQ ≥ 40) intellectual disability (Kaufman Brief 173 
Intelligence Test) was different between groups. A higher proportion of individuals with 174 
moderate intellectual disability was concentrated in the Placebo+CT group, but even so, the 175 
mean IQ in the EGCG+CT group is almost in the cut-off of moderate disability level. Treatment 176 
allocation and randomization was performed by the Hospital del Mar Pharmacy Department 177 
(Table 1) that also was in charge of concealment under a sealed opaque envelope, 178 
randomization sequence generation and supplementation of labeled packs (packs with 179 
identical appearance and size zero blue opaque capsules for EGCG and placebo). All 180 
members of the research team, the statistician, participants with FXS and families and/or 181 
guardians were blind to the allocation to either treatment arm. The double-blind condition was 182 
maintained until the end of the follow-up and data analysis.  183 
Design  184 
The trial design included one month of placebo (run-in period), 3 months of EGCG+CT or 185 
Placebo+CT treatment and 3 months follow up after pharmacological treatment 186 















containing 45% of EGCG (Life Extension Decaffeinated Mega Green Tea Extract; 188 
http://www.lifeextension.com/vitamins-supplements/item00954/mega-green-tea-extract-189 
decaffeinated) or placebo (rice flour). Capsules were prepared ad hoc for the present clinical 190 
trial. Each capsule contained 200 mg of EGCG. All participants were administered two 191 
capsules of EGCG (400 mg; equivalent to 5-7 mg/kg) or placebo, one during lunch and 192 
another during dinner. All participants underwent CT during the entire intervention period 193 
(months 1 to 6 after the run-in period). We provided access to an easy-to-use cognitive 194 
software package (FesKits; www.feskits.com/) connected to a telematics platform that 195 
includes a wide range of training programs and exercises (more than 5.000) training all 196 
cognitive domains. The subjects were specifically trained in memory, executive functions, 197 
language and attention processes. However, memory training was preponderant over the 198 
other cognitive capacities, comprising 50% of each training session. The duration of each 199 
session was recorded to register user compliance. A neuropsychologist monitored the 200 
performance of each subject and we used an algorithm to adapt the difficulty of the task to 201 
learning progression. During the one-month run-in enrolment period, a neuropsychologist 202 
tutored each subject (and their family) to familiarize with the CT telematics platform. All 203 
participants of EGCG and placebo groups were instructed to perform three sessions of 30 to 204 
50 minutes per week. Patients underwent four evaluations: at baseline, after the placebo run-205 
in, at three months after EGCG/placebo treatment initiation, and three months after 206 
EGCG/placebo treatment discontinuation (Figure S1). 207 
Primary and secondary outcome measurements 208 
Primary outcome measures were defined as the changes in cognitive and functional scores, 209 
assessed by means of TESFX battery, from baseline to 3 months after treatment 210 
randomization and 3 months after EGCG or placebo discontinuation (see Supplementary 211 
materials for description of TESFX battery). Secondary outcome measures comprised the 212 















or placebo discontinuation of: 1) neurophysiological parameters: pre-pulse inhibition (PPI); 2) 214 
efficacy biomarkers: changes from baseline in PI3K/mTOR and ERK phosphorylation in 215 
human lymphocytes; 3) body composition (bioelectrical impedance); 4) treatment compliance 216 
and 5) safety evaluation that included reported adverse events/serious adverse events 217 
(AEs/SAEs), vital signs, physical and neurological examinations, electrocardiogram, and 218 
standard hematology, clinical chemistry assessments, and urinalysis. Safety laboratory 219 
parameters included transaminases, gamma glutamyl transferase, alkaline phosphatase, lipid 220 
profile, and urea. 221 
Neuropsychology 222 
We used a customized neuropsychological battery (TESFX), which includes measures of 223 
attention, psychomotor speed, memory, executive functions, language, adaptive and aberrant 224 
behavior, and quality of life and sleep (see Supplementary materials). The TESFX battery was 225 
developed for FXS clinical trials, based on the TESDAD battery for Down syndrome 226 
individuals (NCT01394796) [13]. All neuropsychological outcomes were assessed at baseline, 227 
3 months after treatment randomization, and 3 months after EGCG or placebo discontinuation. 228 
Briefly, attention was assessed with reaction time and span capacity measures using the 229 
Simple Reaction Time task (SRT, CANTAB), psychomotor speed with the Motor Screening 230 
Test (MOT, CANTAB), visual episodic memory and learning using the Paired Associates 231 
Learning (PAL, CANTAB) and the Pattern Recognition Memory test (PRM, CANTAB), and 232 
verbal episodic memory using the Cued Recall Test (CRT). For executive functioning, we 233 
assessed fractioned components of verbal fluency, working memory, planning, mental 234 
flexibility, and inhibitory control. Verbal fluency was measured using the semantic fluency word 235 
generation task (participants were asked to generate as many words as possible in 1 min 236 
belonging to the specified category of animals). Working memory for visual and verbal 237 















recall tests from the Wechsler Adult Intelligence Scale-III (WAIS-III), respectively. Planning 239 
capacity was measured using the Tower of London - Drexel University (ToLDx) and mental 240 
flexibility with the Weigl Color-Form Sort Test. The Cats and Dogs Test was used to assess 241 
response inhibition. Finally, measures of expressive and receptive language were obtained 242 
with the Boston Naming Test and the Token Test, respectively.  243 
We used adult versions of the selected cognitive tests with the exception of four more difficult 244 
tests in which we used adapted versions for intellectual disability: the CRT (verbal episodic 245 
memory), the Cats and Dogs Test (inhibitory control), and the Weigl Color-Form Sort Test 246 
(mental flexibility); and a child version: the ToLDX (planning ability), in all cases to avoid floor 247 
effects. 248 
Everyday life functionality was assessed with questionnaires for the following domains: 249 
adaptive behavior, quality of life, quality of sleep, and problematic behaviors. Measures of 250 
adaptive behavior were obtained with the adult version of the Adaptive Behavior Assessment 251 
System-Second Edition (ABAS-II). Quality of life was assessed with the ‘parents and 252 
guardians’ version of the Kidscreen-27. Quality of sleep was assessed with the Pittsburgh 253 
Sleep Quality Index (PSQI) and problematic behaviors were assessed with the Aberrant 254 
Behavior Checklist-C (ABC-C). 255 
Neurophysiological parameters   256 
We used prepulse inhibition (PPI) of acoustic startle responses (ASR) to evaluate 257 
neurophysiological changes in sensory processing and inhibitory control of brain information. 258 
Participants in the PPI sub-study (31 individuals), underwent three sessions (at baseline, and 259 
at 3 and 6 months after treatment initiation). ASR in the orbicularis oculi muscle were recorded 260 
bipolary from the right eye with surface cup electrodes located 2cm apart, edge to edge, in the 261 
muscle belly, as close to the margin of the lower lid as possible, and the lateral electrode in 262 















Electromyographic (EMG) signals were rectified and amplified with a band pass of 20Hz to 264 
350Hz. Auditory stimulus were delivered after 1-2 minutes of resting time period, by 265 
discharging a magnetic coil of a Medtronic stimulator (MagPro R30) over a metallic platform. 266 
The discharge induces a brief loud click, of approximately 130dB intensity. For the acoustic 267 
prepulse stimulus the coil was discharged at an intensity that was clearly audible but did not 268 
elicited consistent EMG responses. The prepulse preceded the startle stimulus by 50, 100, 269 
150, 200, 500, and 1000 msec. We administered 3 trials for each interinterval stimulus with an 270 
intertrial interval that varied from trial to trial with a range of 20 to 50 seconds. If there was 271 
voluntary EMG activity, trials were rejected prior to data analysis. Participants with no EMG 272 
response following the startle stimulus were considered as non-responders. For trials with 273 
response onset between 20 to 100 msec, peak amplitude of the rectified EMG was measured. 274 
We calculated: (i) the amplitude and latency of the startle response to pulse alone trials and 275 
(ii) the PPI, calculated as the percent decrement in the startle amplitude in the presence of the 276 
prepulse compared with the amplitude without the prepulse: 100 X [(response amplitude in the 277 
startle stimulus alone trials - response amplitude in the prepulse trials)/response amplitude in 278 
the startle stimulus alone trials)]. Average PPI was calculated for each interstimulus interval. 279 
When responses were absent, they were given the value of 0 for calculation of the mean 280 
amplitude.   281 
Biochemical biomarker analysis 282 
Hepatic enzymes (AST-serum glutamic oxaloacetic transaminase, ALT-serum glutamic 283 
pyruvate transaminase, γ-Glutamyl Transferase), lipid profile and oxidation (LDL-low density 284 
lipoprotein, HDL-high density lipoprotein, cholesterol, triglycerides, and oxidized-LDL), urea, 285 
and alkaline phosphatase were evaluated in study participants. We also evaluated the effect 286 
of EGCG on the phosphorylation of the PI3K/mTOR and ERK signaling pathway in human 287 
















Statistical analysis 290 
A description of the baseline characteristics of all study participants included in the analysis is 291 
provided using mean and standard deviation for quantitative variables and absolute and 292 
relative frequencies for qualitative variables. In the case of the IQ, the median and the range 293 
are presented given that IQ is a left-censored variable with lower limit of 40. 294 
The data of the preclinical study corresponding to the comparison of the Fmr1 knockout and 295 
the WT mice were analyzed by means of the t-test and F-test.  296 
The analyses from the clinical trial were performed on data from the modified intention-to-treat 297 
population. To analyze the changes from baseline in scores of primary and secondary 298 
outcomes, including all tests scores, plasma biomarkers, and neurophysiology variables, after 299 
three and six months, respectively, ANCOVA models were used. These models included 300 
treatment, IQ, baseline scores, and the number of training sessions during the respective 301 
study period as independent variables. The effect size measure of all the regression models 302 
fitted was the adjusted mean difference between both treatments with respect to changes from 303 
baseline. This value is an estimation of the expected difference of the changes from baseline 304 
between two persons that receive different treatments but have the same values in the 305 
remaining variables (IQ, baseline score, number of training sessions). The statistical analyses 306 
were performed with the statistical software package R (The R Foundation for Statistical 307 
Computing), version 3.2. Statistical significance was set at 0·05. 308 
Results  309 
Preclinical studies  310 
EGCG improves novel object-recognition memory in the Fmr1 knockout mouse 311 
Fmr1–/y mice showed a marked cognitive deficit in the novel object-recognition memory test 312 















[12,14]. Acute administration of GTE containing EGCG (p.o.) after the training phase improved 314 
novel object-recognition memory in Fmr1–/y mice compared to Fmr1–/y littermates receiving 315 
saline (treatment effect: F(1,19)=5.496, p<0.01) (Fig. 1B). Notably, the dose of 4.5 mg/kg 316 
EGCG was as effective as the doses of 11.25 mg/kg or 22.5 mg/kg (Fig. 1B), pointing to the 317 
possibility of using low doses.  318 
Clinical trial 319 
Subjects, disposition, and dosing 320 
Forty males and four females with ages in the 18-55 years range were assessed for eligibility 321 
for inclusion for the study. From these, thirteen did not enter the study due to exclusion criteria 322 
or lack of motivation to participate. As discussed earlier four additional subjects were excluded 323 
from the study because they did not met FXS molecular diagnosis criteria. Subject disposition 324 
and the composition of the populations are shown in the CONSORT diagram (Fig. 2). The 325 
proportion of individuals that completed all procedures was very similar in both groups. Among 326 
the 27 subjects included in the analyses, there were two dropouts (7.4%) during the study 327 
period: one subject from the Placebo+CT group, who left the study before the 6 months 328 
assessment session due to lack of motivation to continue; one subject from the EGCG+CT 329 
group, who left the study before the 6 months assessment session due to lack of motivation to 330 
participate in the neurophysiological exploration and the biochemical analysis, but agreed to 331 
complete the neuropsychological assessment and therefore these data have been included in 332 
the analyses. Thus, twenty-seven subjects (Table 1) were included in the final analysis.  333 
Pre-specified efficacy analyses 334 
The primary outcome was the change from baseline to 3 months in cognitive and functional 335 
components of the TESFX neuropsychology battery (Data for all the tests are summarized in 336 















Effects of combined treatment with EGCG or placebo and cognitive training (CT) after 3 338 
months of intervention 339 
We found statistically significant effects of EGCG+CT treatment on cognitive measures of 340 
visual episodic memory, but marginal non-significant effects on executive functions.   341 
After three months of treatment, EGCG+CT treated individuals showed better performance on 342 
memory measures of the paired associate visual memory task from the CANTAB battery 343 
(PAL) compared to Placebo+CT with larger changes from baseline in the memory score in the 344 
first trial (Adjusted mean difference (AMD): 6.87; 95%-CI: [2.68,11.05]; p=0·003 Fig. 3A and 345 
Table S1), and in the number of stages completed (AMD: 1.72; [0.20,3.24]; p=0·029), and a 346 
larger decrease of errors per total number of trials (AMD: -63.62; [-110.59,-16.66]; p=0·011; 347 
Fig. 3B and Table S1). These results indicate a benefit on visual memory associated to 348 
EGCG+CT treatment. EGCG+CT treated individuals also showed a higher performance in 349 
planning capacity (Tower of London; TOLDX) that did not reach statistical significance. 350 
EGCG+CT group showed a larger reduction in the total number of moves for solving the items 351 
of the planning task (AMD: -19.42; [-39.38,0.54]; p=0·056) compared to the placebo group.  352 
Regarding the impact of treatment on functional abilities, significant positive effects of 353 
EGCG+CT intervention were shown on adaptive behavior. EGCG+CT treated individuals 354 
showed an improvement in the ABAS-II home living score compared to baseline (AMD: 10.8; 355 
[2.05,19.55]; p=0·018) (Figure 3C and Table S1), whereas Placebo+CT group showed a mild 356 
decrease. No significant improvement was detected in the other skill areas: communication 357 
abilities, community use, functional academics, health and safety, leisure, self-care, self-358 
direction, social interaction, and working/labor skills), or in the total ABAS score. No 359 
statistically significant improvement of Placebo+CT group over EGCG+CT treated individuals 360 
















6 months follow-up upon cessation of EGCG/placebo administration  363 
During months 3 to 6, we discontinued EGCG and placebo, but both groups continued 364 
receiving CT. At 6 months, consistent positive effects persisted on visual episodic memory 365 
(CANTAB battery PAL) although to a lesser extent than at 3 months of treatment. A slight 366 
improvent in adaptive behavior and new beneficial effects emerged on attention, quality of life 367 
and, marginally, on executive functions in the EGCG+CT group. Regarding visual episodic 368 
memory, patients in the EGCG+CT group showed a significantly better performance in the 369 
paired associates visual learning task (CANTAB battery PAL), upon EGCG discontinuation, 370 
achieving a larger reduction of errors per number of trials (AMD: -47.80; [-94.00, -1.61]; 371 
p=0.043) compared to Placebo+CT. In the simple reaction attention task, the group treated 372 
with EGCG+CT showed a statistically significant larger reduction in latency and a larger 373 
increase in the number of correct trials compared to Placebo+CT (SRT mean latency: -251.15; 374 
[-396·19, -106.11]; p=0·003; SRT total correct trials: 19.12; [0.28, 37.96]; p=0·047), although 375 
for both parameters the beneficial effect were slightly lower than at 3 months. Positive effects 376 
emerged on executive functions regarding mental flexibility, inhibition and working memory. 377 
Although not reaching statistical significance, a larger increase of the total score in the mental 378 
flexibility Weigl test (AMD: 1.32; [-0.01, 2.65]; p=0·051), a decrease in the number of errors in 379 
the inhibition Cats and Dogs test (AMD: -3.12; [-5.52,-0.73] p=0.055), and an increase in the 380 
retention of the reverse span length in verbal working memory in the Digit span test, with 381 
(AMD: 0.81; [-0.03, 1.65]; p=0·058) were observed.  382 
In the functional domain, the statistically significant differences with respect to the changes 383 
from baseline in adaptive behavior achieved in the ABAS-II home living subscale score during 384 
EGCG+CT treatment persisted after 3 months discontinuation (AMD: 10.62; [1.98,19.26]; 385 
p=0·019) (Table S1). In addition, in the EGCG+CT group we observed larger differences from 386 
baseline in the quality of life scores in the Kidscreen-27 regarding physical wellbeing (AMD: 387 















statistically significant improvement of Placebo+CT group was observed in the functional 389 
domain compared to EGCG+CT group. 390 
Cognitive training (CT) compliance  391 
Compliance with CT was considered poor in both treatment groups although the number of CT 392 
sessions was different. After 3 months, both groups showed a similar number of training 393 
sessions accounting for about 2 weekly sessions on average. The mean number of sessions 394 
performed by Placebo+CT group was 23.5 ± 23.1, whereas EGCG+CT group performed 21.7 395 
± 15.7. Compliance with the cognitive stimulation program in the last 3 months after 396 
EGCC/placebo discontinuation improved in the Placebo+CT group but not in the EGCG+CT 397 
group. After 6 months, the mean number of sessions performed by Placebo+CT group was 398 
36.7 ± 41.6 sessions, whereas the EGCG+CT group accounted for 28.1 ± 24.8.  399 
Neurophysiology  400 
From the 31 individuals that participated in the neurophysiology study, two were considered 401 
non-responders. One individual of the Placebo+CT group dropped out the study after the 3 402 
months. The data of four individuals were not considered of sufficient quality for the analysis in 403 
one the measurements points. The amplitude of acoustic startle responses and the 404 
percentage of prepulse inhibition (PPI) were analyzed in both groups at each interstimulus 405 
interval (ISI), at baseline, after 3 months of treatment or placebo and after 3 months treatment 406 
discontinuation. At baseline, the average percentage of PPI amplitude for the ISI of 50 msec. 407 
was 25,9% (SD: 43,8) for EGCG+CT group and 37,8%±51,6 for Placebo+CT group, 408 
41,4%±53,5 and 49,8% ±35,4 for the ISI of 100 msec; 35,5%±61 and 57%±42 for the ISI of 409 
150 msec; 33,7%±50,5 and 56,9%±37,1 for the ISI of 200 msec. and 9,52%±59,1 and 410 
45,3%±33,2 for the ISI of 500 msec. Differences from baseline, after 3 and 6 months were 411 
calculated for both groups and adjusted for baseline values, cognitive stimulation and the IQ 412 















msec a marginal tendency to significance (Eff.-32.39; p-value=0.07) was observed on the 414 
estimation differences between treatments after 6 months.  415 
Safety 416 
All adverse events occurring in more than one subject are listed in Table S2. Eighteen 417 
adverse events were reported throughout the clinical trial by thirteen patients that were equally 418 
distributed between both groups. From these, 16 adverse events were considered mild non-419 
serious (12 in the EGCG+CT group and 6 in the Placebo+CT group). Two serious adverse 420 
events were reported by the same individual of the EGCG+CT group, who was hospitalized for 421 
a gallstone, which required cholecystectomy in a second hospitalization. This subject already 422 
reported pain episodes that could be related to gallstone prior to entering the study. This 423 
adverse effect was not considered related to EGCG. There were no withdrawals related to 424 
drug tolerability. No significant differences were detected for the safety biomarkers explored 425 
(see Table S3) Therefore, we can conclude that EGCG compound is safe and well tolerated in 426 
FXS young adults at the dose administered in our study.  427 
 428 
Discussion  429 
The aim of the present study was to investigate the safety and potential benefits of EGCG for 430 
improving cognition and everyday life functionality in FXS. Our study showed that EGCG is 431 
safe and active on cognitive function. In young adult Fmr1 knockout mice (Fmr1–/y), acute 432 
administration of three different doses of EGCG rescued object recognition memory deficits 433 
detected in non-treated Fmr1–/y mice. In our clinical trial, EGCG combined with cognitive 434 
training (CT) improved performance on cognitive measures of visual associative memory and 435 
had a positive impact on home living adaptive skills after a short treatment period of 3 months 436 
compared to Placebo+CT. However, no beneficial effects were detected in executive 437 
functioning. The amelioration in home living adaptive skills imply increased self-autonomy for 438 















preparing meals, tiding up, cleaning, and using domestic equipment, allowing a higher daily 440 
competence in EGCG+CT treated individuals. After discontinuing the EGCG treatment, while 441 
continuing CT, sustained effects persisted on episodic memory and home living adaptive 442 
skills, and new significant improvements emerged in the EGCG-CT group on attention, which 443 
were accompanied by a significant improvement of quality of life perception on measures of 444 
physical wellbeing and parent relationship. In addition, marginal non-significant beneficial 445 
effects were observed on executive functions. This wide spectrum of gains was not observed 446 
in the Placebo+CT group, suggesting that the combination of EGCG and CT is most effective. 447 
We speculate that the effects of EGCG could be related to an improvement in hippocampal 448 
functional networks, since in Fmr1–/y mouse, EGCG rescued hippocampal-dependent 449 
memory deficits (object recognition) and the main effect in patients was an improvement of 450 
immediate visual episodic memory sensitive to hippocampal dysfunction. These results, along 451 
with our previous clinical and preclinical cognitive and neuroimaging studies in Down 452 
syndrome [4], suggest that EGCG is probably acting upon brain distributed hippocampal-453 
prefrontal functional networks supporting memory, and attention [3,4]. Noteworthy, a short-454 
term period of 3 months under EGCG+CT combined intervention was sufficient for inducing 455 
significant functional changes in everyday life in our sample of FXS individuals. As previously 456 
observed in Down syndrome, cognitive and functional gains remained very stable and new 457 
emerged after 6 months related to EGCG+CT combined intervention. These results could be 458 
interpreted as CT maintenance after ceasing EGCG administration in the last 3 months would 459 
be contributing to sustain EGCG effects and may suggest that CT is an effective co-adjuvant 460 
for enhancing or sustaining EGCG effects. More studies are required to explore this notion. 461 
We also aimed at detecting possible changes in neurophysiological parameters. FXS patients 462 
have reduced prepulse inhibition (PPI) than normal subjects, indicating impairment of 463 
sensorimotor gating [15]. We obtained similar results at baseline, but we did not detect 464 















the neurophysiological behavior of the FXS population, the large PPI impairment and the low 466 
number of subjects that finally were analyzed could explain this lack of positive results. Larger 467 
sample sizes in future studies are necessary to find differences between treatment groups.  468 
Regarding the possible mechanism of action of EGCG, we wanted to assess whether EGCG 469 
had an impact on mTOR phosphorylation cascade that could explain the positive effects on 470 
cognition [16,17]. EGCG has been proven to inhibit mTOR and reduce phosphorylation of 471 
downstream Akt [18]. However, we could not observe a homogenous increase in 472 
phosphorylation in basal conditions or a consistent decrease in phosphorylation after 3 473 
months of treatment. Thus, we cannot confirm whether EGCG is having an effect on mTOR 474 
phosphorylation.  475 
EGCG+CT did not produce detectable adverse effects. Severe adverse events were only 476 
reported in two occasions (same subject) associated to a premorbid medical condition and not 477 
to EGCG. As such, we conclude that EGCG is safe and well tolerated in FXS young adults at 478 
the dose administered in our study.  479 
 480 
The study had some limitations. Our study was exploratory and with short-term administration, 481 
and thus phase 2 trials with a larger population and longer follow up periods under treatment 482 
in individuals with FXS will be needed to confirm the present results. Second, due to the large 483 
number of tests done in the framework of the regression models, the family-wise error rate 484 
exceeded 0.05. To protect against type II errors, no corrections for multiple comparisons were 485 
applied. Third, further studies are needed to rule out the possibility that any of the significant 486 
results was a type I error. Fourth, cognitive training differences in both treatment conditions 487 
after 6 months may have biased our results, given the higher attrition observed in the 488 
Placebo+CT against EGCG+CT. Even so, positive effects were detected in the former group. 489 
Fifth, the fact that there is still no consensus gold standard for testing cognitive changes in 490 















caveat when interpreting the results of this study. However, valid, reliable, standardized, 492 
sensitive tests to mild cognitive changes where used, fact that allows replicating, comparing 493 
and validating our findings in future clinical trials.  Sixth, it could be stated that sex was not 494 
included as a key variable for the randomization process nor as a predictor in the statistical 495 
analyses. The proportion of women was small, so we chose to balance and adjust for IQ to 496 
maintain the statistical power of our analyses with our reduced sample size. Thus, we do not 497 
expect that sex may have contributed to bias our results. 498 
 499 
Conclusion   500 
This Phase I study provides support to the benefits of using EGCG combined with CT as a 501 
promising therapeutic intervention for improving cognition, functionality in everyday life in 502 
adults with FXS, in the absence of substantial adverse effects.  503 
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Figure and Tables Legends 658 
Figure 1. The cognitive deficit in the novel object-recognition memory test of Fmr1–/y mice is 659 
sensitive to acute GTE administration. A) Fmr1–/y mice show a significant impairment in the 660 















of decreasing concentrations of GTE (22.5, 11.25 or 4.5 mg/kg, p.o.) was enough to 662 
significantly improve the memory performance of Fmr1–/y mice assessed 24 h later. Data are 663 


































Figure 3. Effects of combined treatment with EGCG+CT and Placebo+CT on 670 
neurocognitive performance and adaptive behavior. Data correspond to treatment effects 671 
at 3months, and after a washout period of 3 months (mean differences from baseline and 95% 672 
confidence intervals). (A) Effects of EGCG+CT vs. Placebo+CT over time in the response of 673 
Paired Associates Learning memory task for first trial memory score, (B) Paired Associates 674 
Learning memory task for total errors, and (C) and in adaptive behavior in the ABAS II-Home 675 






























Table 1. Sociodemographic characteristics and clinical parameters at baseline  678 
 679 
    Placebo+CT  EGCG+CT 
Participants characteristics n= 12  n=15 
  Gender1    
  Male  11 (91.7%)  12 (80%) 
  Female 1 (8.3%)  3 (20%) 
  Age2 39.5 (8.2)  32.9 (10) 
  FMR11     
  Full mutation 10 (83.3%)  11 (73.3%) 
  Mosaicism 2 (16.7%)  4 (26.7%) 
  BMI2 26.5 (3.2)  27.6 (4.3) 
  IQ3 41.5 (40 – 60)  55 (40 – 88) 
  Intellectual disability level1    
 Mild 2 (16.7%)  8 (53.3%) 
 Moderate 10 (83.3%)  7 (46.7%) 
 680 
Placebo+CT: Placebo + Cognitive Training group and EGCG+CT: EGCG + Cognitive Training group. 681 
BMI: body mass index; IQ: intelligence quotient 682 
(1) Number of subjects and (percentage), (2) Mean and (standard deviation), (3) Median and (range). 683 
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